NCT06023186View on ClinicalTrials.gov

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

RecruitingOBSERVATIONAL

Enrollment

20

Participants

Timeline

Start Date

November 3, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

September 30, 2026

Conditions

Obstructive Hypertrophic Cardiomyopathy

Interventions

DRUG

mavacamten

Study participants will receive mavacamten under the standard of care

Trial Locations (1)

22908

RECRUITING

University of Virginia, Charlottesville

Sponsors

Lead Sponsor

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Michael Ayers

OTHER

NCT06023186 - Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM | Biotech Hunter | Biotech Hunter